ESC 2019 — ACS with planned invasive evaluation: prasugrel bests ticagrelor


  • Emily Willingham, PhD
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients with acute coronary syndrome (ACS) with ST-segment elevation myocardial infarction (STE[MI]) or not (NSTEMI) and for whom invasive evaluation is planned have reduced 1-year mortality/MI/stroke with prasugrel vs ticagrelor.

Why this matters

  • Both prasugrel and ticagrelor have class I recommendation for ACS, STEMI, or NSTEMI, but the relative 1-year outcomes with these drugs for patients planned for invasive evaluation are not clear.
  • The authors note that this trial not only compared 2 drugs but also 2 antiplatelet treatment strategies (pretreatment with ticagrelor vs deferred prasugrel loading after establishing coronary anatomy in NSTEMI).
  • In an unofficial Twitter poll during the conference, 51% of 158 respondents said prasugrel would now be their first choice, 15% said it would be ticagrelor, and 35% said they would individualize treatment.

Results

  • 1-year any-cause mortality/MI/stroke rates with ticagrelor vs prasugrel:
    • 9.3% vs 6.9%.
    • HR, 1.36 (95% CI, 1.09-1.70; P=.006).
  • Similar outcomes for composite of cardiovascular death/MI/stroke.
  • MI drove composite results.
  • Major bleeding was similar between groups.
  • At 1 year, 15.2% with ticagrelor and 12.5% with prasugrel had discontinued therapy (P=.03). 

Study design

  • Multicenter (21 centers in Germany, 2 in Italy), randomized, open-label trial; 4018 patients with ACS (41.1% suspected STEMI, 46.2% suspected NSTEMI, remainder unstable angina) who were having invasive evaluation were randomly assigned to ticagrelor (n=2012) or prasugrel (n=2006) strategies.
  • Funding: German Center for Cardiovascular Research; Deutsches Herzzentrum München.

Limitations

 

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit